Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis

PHASE2CompletedINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

October 12, 2012

Primary Completion Date

October 9, 2014

Study Completion Date

June 17, 2015

Conditions
Postmenopausal Osteoporosis (PMO)
Interventions
DRUG

Romosozumab

Administered by subcutaneous injection

DRUG

Placebo

Administered by subcutaneous injection

Trial Locations (27)

446-0063

Research Site, Anjyo-shi

814-0165

Research Site, Fukuoka

800-0057

Research Site, Kitakyushu-shi

832-0059

Research Site, Yanagawa-shi

509-6134

Research Site, Mizunami-shi

063-0814

Research Site, Sapporo

065-0024

Research Site, Sapporo

020-0066

Research Site, Morioka

223-0062

Research Site, Yokohama

231-0861

Research Site, Yokohama

602-8026

Research Site, Kyoto

981-3132

Research Site, Sendai

983-0862

Research Site, Sendai

881-0113

Research Site, Saito-shi

390-1401

Research Site, Matsumoto-shi

386-0151

Research Site, Ueda-shi

386-0405

Research Site, Ueda-shi

559-0011

Research Site, Osaka

569-1123

Research Site, Takatsuki-shi

362-0806

Research Site, Kita-adachi-gun

192-0046

Research Site, Hachioji-shi

204-0021

Research Site, Kiyose-shi

108-0075

Research Site, Minato-ku

146-0094

Research Site, Ōta-ku

140-0011

Research Site, Shinagawa-ku

166-0003

Research Site, Suginami-ku

171-0033

Research Site, Toshima-ku

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY